U.S. Pharma Stock News

Eli Lilly recently reported past fourth-quarter 2025 and full-year results showing higher sales and net income, issued 2026 revenue guidance of US$80.00 billion to US$83.00 billion, completed US$4.08 billion of share repurchases under its 2024 buyback, and agreed to acquire Orna Therapeutics for up to US$2.40 billion in cash. Together with preparing substantial pre-launch inventory for its experimental oral GLP-1 pill orforglipron, these moves highlight how Eli Lilly is reinforcing its...

In February 2026, Leggett & Platt reported that fourth-quarter 2025 sales fell to US$938.6 million from US$1,056.4 million a year earlier, while net income rose to US$25.2 million and full-year 2025 results swung from a US$511.5 million loss to a US$235.4 million profit. The company also confirmed it has effectively completed a multi-year restructuring, reduced leverage through the sale of its Aerospace business, and issued 2026 guidance calling for US$3.8 billion–US$4.0 billion in sales and...

Recent performance snapshot for Yum China Holdings (YUMC) Without a specific headline event driving attention today, Yum China Holdings (YUMC) still gives investors a few data points to work with, from recent share performance to headline revenue and profitability. See our latest analysis for Yum China Holdings. Yum China’s recent 1 day share price return of 3.3% sits within a stronger 30 day share price return of 17.37% and a 1 year total shareholder return of 15.09%, while 3 and 5 year...

Birkenstock Holding (NYSE:BIRK) reported robust first quarter revenue growth that exceeded its full year guidance. The company highlighted broad based strength across regions, with especially rapid expansion in APAC. Birkenstock continued to grow its global retail footprint and advanced its push toward four season footwear offerings. Management approved a new €200 million share repurchase program, signaling confidence in the brand and balance sheet. Birkenstock comes into this update with...

Keysight Technologies (KEYS) is drawing fresh attention after launching SOS Enterprise, an advanced engineering data management platform aimed at automating governance, traceability, compliance, and AI readiness across complex, multi site semiconductor and electronics workflows. See our latest analysis for Keysight Technologies. The SOS Enterprise launch lands at a time when momentum in Keysight’s share price has been building, with a 30 day share price return of 11.51% and a 90 day share...

Group 1 Automotive (GPI) caught investor attention after its board approved a 10% increase in the 2026 annual dividend rate to $2.20 per share, with a $0.55 quarterly payment scheduled for March. See our latest analysis for Group 1 Automotive. Even with the dividend increase, recent trading has been softer. The 30-day share price return is 16% and the year-to-date share price return is 14.96%, contributing to a 1-year total shareholder return of 30.32%. The 3- and 5-year total shareholder...

FuboTV (FUBO) has drawn fresh attention as investors reassess its live TV streaming model, with the stock recently closing at US$1.34 after mixed short term share price performance. See our latest analysis for FuboTV. That latest move comes after a sharp reset in sentiment, with a 30 day share price return of 48.06% decline and a 90 day share price return of 62.88% decline, pointing to fading momentum despite the modest 1 day share price gain. If FuboTV’s swings have you reassessing your...

ECARX Holdings (NasdaqGM:ECX) closed out FY 2025 with Q4 revenue of US$304.7 million and basic EPS of US$0.01, alongside net income of US$2.6 million. On a trailing twelve month basis, the company recorded total revenue of US$847.9 million and a basic EPS loss of US$0.19, reflecting ongoing pressure at the bottom line. The company has reported revenue between US$198.2 million and US$304.7 million over the past six quarters, with quarterly basic EPS ranging from a loss of US$0.14 to a small...

If you are wondering whether Marvell Technology at around US$78.61 is a bargain or a value trap, this article walks through what the numbers are actually saying about the stock. The share price is around US$78.61, with returns of a 2.1% decline over 7 days, a 3.2% decline over 30 days, a 12.1% decline year to date, but 80.1% over 3 years and 54.6% over 5 years, which can leave investors unsure how to interpret the current setup. Recent news flow around Marvell has focused on its role in key...

Digital Turbine (APPS) is back on investors’ radar after raising its 2026 revenue outlook to US$553 million to US$558 million and reporting third quarter results that showed a shift from a net loss to net income. See our latest analysis for Digital Turbine. The recent guidance hike and return to quarterly net income have arrived during a weak patch for the stock, with a 30 day share price return of a 20.04% decline and a 1 year total shareholder return of a 32.31% loss indicating that...

What RingCentral’s index additions could mean for investors RingCentral (RNG) has just been added to the S&P 1000, S&P SmallCap 600, S&P Composite 1500, and the S&P 600 Information Technology sector index. This places the stock directly in front of index tracking money. See our latest analysis for RingCentral. The index additions have arrived alongside a stretch of stronger share price momentum, with a 1 day share price return of 6.30% and a 7 day share price return of 11.69%. However, the 1...

AFG stock moves and recent performance snapshot American Financial Group (AFG) has drawn fresh investor attention after recent trading, with the stock closing at $128.95 and showing mixed short term and longer term total returns across different holding periods. See our latest analysis for American Financial Group. While the recent 1 month share price return of 2.19% decline and 3 month share price return of 9.47% decline suggest fading short term momentum, the 1 year total shareholder return...

Alliance Resource Partners (ARLP) moved into focus after President Donald Trump signed an executive order directing the Department of War to prioritize electricity purchases from coal fired plants and to commit US$175 million to upgrade six coal facilities. See our latest analysis for Alliance Resource Partners. The policy boost comes on top of steady market gains, with a 7 day share price return of 5.95% and a year to date share price return of 10.86%, while the 5 year total shareholder...

Ultragenyx Pharmaceutical (RARE) just closed out FY 2025 with fourth quarter revenue of US$207 million and a basic EPS loss of US$1.29, while trailing twelve month revenue came in at US$673 million against a TTM basic EPS loss of US$5.83. The company has seen quarterly revenue move from US$164.9 million in Q4 2024 to US$207 million in Q4 2025, alongside quarterly basic EPS losses ranging between US$1.17 and US$1.81 over the year. For investors, the latest numbers keep the focus squarely on...

If you are wondering whether American Superconductor’s share price still makes sense at current levels, this article walks through what the numbers say about value rather than hype. The stock recently closed at US$34.26, with returns of 21.6% over 7 days, 9.6% over 30 days, 8.5% year to date, 9.9% over 1 year and a very large gain over 3 years, with a 5 year return of 31.9%. These moves have put American Superconductor back on many investors’ watchlists, as they reassess whether the current...

In February 2026, Organon & Co. reported fourth-quarter 2025 sales of US$1,507 million, moving from net income of US$109 million a year earlier to a net loss of US$205 million, while also affirming a quarterly dividend of US$0.02 per share and issuing cautious 2026 revenue guidance of about US$6.2 billion. Alongside the weaker earnings and flat outlook, Organon secured FDA approval to extend Nexplanon’s use from three to five years and completed the Jada divestiture, steps that could reshape...

SoundHound AI highlighted new Agentic Voice Commerce platforms at CES 2026, showcasing expanded applications for its conversational AI. The company also announced fresh partnerships aimed at bringing its voice solutions into more consumer and enterprise settings. These product launches and collaborations arrive during a period of sharp share price swings for NasdaqGM:SOUN. NasdaqGM:SOUN closed at $7.46, with returns of 85.6% over three years but declines of 12.9% over the past week, 33.9%...

Kimco Realty (NYSE:KIM) has approved a 4% increase to its quarterly common dividend for 2025. The company reported record overall portfolio occupancy for 2025. Kimco also recorded its highest quarterly new leasing volume in more than 10 years. Kimco Realty, a major owner of open air shopping centers, sits at the intersection of retail property and consumer spending trends. For investors following real estate income names, a 4% dividend increase from NYSE:KIM and record portfolio occupancy...

Q2 Holdings (QTWO) just paired strong fourth quarter and full year 2025 results with fresh 2026 guidance, combining double digit revenue growth, higher profitability, and an updated outlook on subscription and AI driven digital banking services. See our latest analysis for Q2 Holdings. Despite the upbeat earnings and guidance, Q2 Holdings' recent share price performance has been weak. The 30 day share price return is 22.61% and the 90 day share price return is 26.53%, while the 1 year total...

QuantumScape launched its Eagle Line pilot production line, targeting scalable solid state battery output. The company integrated its Cobra manufacturing process into Eagle Line to support higher volume production. QuantumScape expanded agreements with major automotive OEMs and recorded its first customer billings. PowerCo shifted to a licensing only model with QuantumScape, changing the risk and capital mix of that relationship. The company moved into non automotive markets such as data...

CBL & Associates Properties (CBL) has just posted its FY 2025 third quarter numbers, with total revenue of US$139.3 million, basic EPS of US$2.44, and net income of US$74.3 million setting the tone for the latest update. The company has seen revenue move from US$125.1 million in Q3 FY 2024 to US$139.3 million in Q3 FY 2025, while trailing twelve month basic EPS stands at US$4.06, alongside a net profit margin of 22.3% versus 6.1% a year earlier, helped by a US$131.2 million one off gain...

If you are wondering whether Sanmina shares are still worth considering after a strong run, this article will walk through what the current price could mean for underlying value. The stock trades at US$145.81 after a 2.7% decline over the last 7 days and a 12.7% decline over the last 30 days, while the 1 year return sits at 62.6% and the 3 year return at 129.5%. Recent attention on Sanmina has been driven by ongoing interest in electronics manufacturing services and how companies in this...

CRISPR Therapeutics expanded global access to CASGEVY, with additional regulatory approvals and reimbursement decisions supporting wider patient use. The company reported significant progress across its clinical and preclinical pipeline, including programs in autoimmune diseases and oncology. These developments highlight operational momentum across multiple therapeutic areas for CRISPR Therapeutics, ticker NasdaqGM:CRSP. For investors tracking CRISPR Therapeutics at a share price of $53.07,...

AVITA Medical (RCEL) has just wrapped up FY 2025 with Q4 revenue of US$17.6 million, a basic EPS loss of US$0.38, and net income loss excluding extra items of US$11.6 million, giving investors a clear read on how the year finished. Over recent quarters, the company has seen revenue range from US$17.1 million to US$18.5 million, while quarterly basic EPS losses have moved between US$0.38 and US$0.53 as management pushes ahead with commercial execution and product launches. For investors, the...